Addressing Time Constraints for European Cell Therapy Raw Materials

Cryoport Systems, a subsidiary of Cryoport, Inc. (CYRX), has opened a 1,300-square-meter GMP-compliant IntegriCell cryogenic storage facility in Villers-le-Bouillet, Belgium, in 2024. Fresh leukopaks typically experience a decline in cell viability after 24-48 hours, making long-distance transport and production schedules critical factors in maintaining raw material quality. The Belgium facility aims to freeze samples within 24 hours of collection, reducing transportation risks between European hospitals and manufacturing facilities. This also ensures batch reproducibility and supply continuity, which are essential when transitioning from clinical trials to commercial production.

IntegriCell Standardizes Manufacturing Processes

IntegriCell utilizes automated closed-process (ACP) technology to perform washing, cell concentration adjustment, addition of CryoStor CS10, and controlled-rate freezing, achieving over 90% recovery and viability after thawing. The closed-loop process minimizes contamination and operator variability, decoupling collection schedules from manufacturing timelines and improving facility utilization. The Belgium center will also serve as a European hub for developing, optimizing, and validating processes before transferring them to other Cryoport facilities. This infrastructure supports cell therapy manufacturing for customers, from early-stage clinical trials to commercial products.

Approved CAR-T Therapies Drive Demand

Novartis (NVS)'s Kymriah (tisagenlecleucel), a CD19-targeted autologous CAR-T therapy, received FDA approval on August 30, 2017, following a 10-0 recommendation for approval by the FDA advisory committee. Gilead Sciences (GILD)'s Kite Pharma's CD19-targeted Yescarta (axicabtagene ciloleucel) was approved on October 18, 2017, without requiring a separate FDA advisory committee review. Bristol Myers Squibb (BMY)'s Abecma (idecabtagene vicleucel), a BCMA-targeted autologous CAR-T therapy, and Johnson & Johnson (JNJ) and Legend Biotech (LEGN)'s Carvytki (ciltacabtagene autoleucel) received FDA approval on March 26, 2021, and February 28, 2022, respectively, and are currently marketed. While CD19/BCMA bispecific antibodies and hematopoietic stem cell transplantation represent competing therapies, the need for a defined chain of identity for patient-specific cells continues to drive demand for specialized preservation and logistics services.

Growth Market, but Utilization Rates Determine Profitability

The global cell cryopreservation market is projected to grow from USD 9.5 billion in 2025 to USD 36.4 billion in 2032, with a compound annual growth rate of 21.1%. Cryoport competes with BioLife Solutions (BLFS), UPS (UPS)'s Marken, and Thermo Fisher Scientific (TMO) by integrating preservation, biostorage, condition monitoring, and transportation. Localized European operations reduce shipping failures and raw material disposal costs, and deeper integration with customer processes can increase switching costs and recurring revenue. The establishment of this facility did not involve any acquisition, licensing agreements, upfront payments, milestone payments, royalty payments, or equity investments; its success will be measured by customer acquisition and increased throughput.